The clinical significance of plasma soluble programmed cell death ligand 1 (sPD-L1) and vascular endothelial growth factor (VEGF) for non-small cell lung cancer (NSCLC) treated with the combination of anti-angiogenic therapy and anti-PD-L1 antibody (Ab) remain unknown. This study aimed to explore the association between plasma sPD-L1 and VEGF levels and the prognosis of NSCLC patients treated with the combination of Envafolimab and Endostar. Peripheral blood samples were collected from 24 NSCLC patients at baseline and after 6 weeks of treatment and were detected for sPD-L1 and VEGF levels. Both baseline and posttreatment sPD-L1 were significantly higher in progressive disease (PD) group than in controlled disease (CD) group (median: 77.5 pg/ml vs. 64.6 pg/ml, P = 0.036, median: 8451 pg/ml vs. 5563 pg/ml, P = 0.012). In multivariate analysis, lower baseline sPD-L1 levels were significantly associated with longer progression-free survival (PFS) (HR = 6.834, 95% CI: 1.350-34.592, P = 0.020). There were significantly higher posttreatment VEGF levels in PD group compared with CD group (median: 323.7 pg/ml vs. 178.5 pg/ml, P = 0.009). Higher posttreatment VEGF levels were significantly associated with shorter PFS in multivariate analysis (HR = 5.911, 95% CI: 1.391-25.122, P = 0.016). Plasma sPD-L1 and VEGF levels are associated with the clinical response and prognosis of NSCLC patients treated with the combination of PD-L1 inhibitors and anti-angiogenetic therapy.

中文翻译：

---

血浆 sPD-L1 和 VEGF 水平与接受联合免疫治疗的 NSCLC 患者的预后相关。

血浆可溶性程序性细胞死亡配体1（sPD-L1）和血管内皮生长因子（VEGF）对抗血管生成治疗和抗PD-L1抗体联合治疗非小细胞肺癌（NSCLC）的临床意义(Ab) 仍然未知。本研究旨在探讨血浆 sPD-L1 和 VEGF 水平与接受 Envafolimab 和 Endostar 联合治疗的 NSCLC 患者预后之间的关系。收集 24 名 NSCLC 患者在基线时和治疗 6 周后的外周血样本，并检测 sPD-L1 和 VEGF 水平。进展性疾病 (PD) 组的基线和治疗后 sPD-L1 均显着高于疾病控制 (CD) 组（中位值：77.5 pg/ml 对比 64.6 pg/ml，P = 0.036，中位值：8451 pg/ml 对比.5563 皮克/毫升，P = 0.012）。在多变量分析中，较低的基线 sPD-L1 水平与较长的无进展生存期 (PFS) 显着相关（HR = 6.834，95% CI：1.350-34.592，P = 0.020）。PD组治疗后VEGF水平显着高于CD组（中位值：323.7 pg/ml vs. 178.5 pg/ml，P = 0.009）。多变量分析显示，较高的治疗后 VEGF 水平与较短的 PFS 显着相关（HR = 5.911，95% CI：1.391-25.122，P = 0.016）。血浆 sPD-L1 和 VEGF 水平与接受 PD-L1 抑制剂和抗血管生成治疗联合治疗的 NSCLC 患者的临床反应和预后相关。